4.7 Review

Advancements in Chitosan-Based Nanoparticles for Pulmonary Drug Delivery

期刊

POLYMERS
卷 15, 期 18, 页码 -

出版社

MDPI
DOI: 10.3390/polym15183849

关键词

lung diseases; pulmonary drug delivery; lung delivery; chitosan; chitosan derivatives; nanoparticles

向作者/读者索取更多资源

The evolution of respiratory diseases, including emerging respiratory diseases caused by coronavirus family, presents a major public health challenge. Nanomedicine, specifically pulmonary drug delivery using chitosan nanoparticles, has shown potential in optimizing treatment efficacy by increasing drug bioavailability and reducing side effects. The unique biological properties of chitosan nanoparticles, such as anti-inflammatory and antimicrobial capabilities, make them advantageous as nanocarriers for drug delivery to the lungs.
The evolution of respiratory diseases represents a considerable public health challenge, as they are among the leading causes of death worldwide. In this sense, in addition to the high prevalence of diseases such as asthma, chronic obstructive pulmonary disease, pneumonia, cystic fibrosis, and lung cancer, emerging respiratory diseases, particularly those caused by members of the coronavirus family, have contributed to a significant number of deaths on a global scale over the last two decades. Therefore, several studies have been conducted to optimize the efficacy of treatments against these diseases, focusing on pulmonary drug delivery using nanomedicine. Thus, the development of nanocarriers has emerged as a promising alternative to overcome the limitations of conventional therapy, by increasing drug bioavailability at the target site and reducing unwanted side effects. In this context, nanoparticles composed of chitosan (CS) show advantages over other nanocarriers because chitosan possesses intrinsic biological properties, such as anti-inflammatory, antimicrobial, and mucoadhesive capacity. Moreover, CS nanoparticles have the potential to enhance drug stability, prolong the duration of action, improve drug targeting, control drug release, optimize dissolution of poorly soluble drugs, and increase cell membrane permeability of hydrophobic drugs. These properties could optimize the performance of the drug after its pulmonary administration. Therefore, this review aims to discuss the potential of chitosan nanoparticles for pulmonary drug delivery, highlighting how their biological properties can improve the treatment of pulmonary diseases, including their synergistic action with the encapsulated drug.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据